DXR

Daxor Corp. 10-K Summary (Fiscal Year Ended Dec 31, 1999)

Business Context and Reporting Period

Daxor Corporation is a medical device manufacturer and biotech service provider reporting for the fiscal year ended December 31, 1999. The company operates two primary segments: the development and marketing of the BVA-100 Blood Volume Analyzer (FDA cleared in mid-1998) and biotech services through its wholly-owned subsidiary, Scientific Medical Systems (Idant), which provides long-term autologous blood and semen banking. As of March 28, 2000, the company had 4,692,909 shares of common stock outstanding.

Key Financial Metrics

Note: Operating revenues represent less than 20% of total revenues; the majority of income is derived from investment activities.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 10.3% to $2.9 million, driven by a 54% increase in operating revenues ($500,969 vs. $324,192) and higher gains on the sale of investments.
• Improved Profitability: The net loss narrowed significantly to $97,130 from $420,460 in 1998, primarily due to increased investment gains and higher operating revenue.
• Asset Base Contraction: Total assets decreased by approximately $8.2 million, largely due to a decline in the fair value of the marketable securities portfolio (from $43.0 million to $34.9 million).
• Debt Increase: Short-term debt increased by $393,245, consisting of bank loans and margin debt secured by marketable securities.
• Operational Restoration: Laboratory operations (blood and semen banking), which were restricted in 1998, were restored to full function in February 1999 following a negotiated settlement.

Guidance, Outlook, and Risks

Outlook and Strategy: Management anticipates that the BVA-100 Blood Volume Analyzer will become the primary revenue source in the immediate future. In Q1 2000, the company began active marketing, placing or receiving orders for 12 instruments (10 outright sales). The company estimates a potential market of 15-20 million tests annually.

Management Commentary: Preliminary clinical data suggests the BVA-100 can significantly reduce mortality in septic shock patients by identifying hypovolemia. The company is also exploring partnerships with blood substitute and stimulant manufacturers.

Risks and Contingencies:

• Market Acceptance: The primary risk is demonstrating the cost-effectiveness and accuracy of the BVA-100 to achieve widespread hospital adoption.
• Liquidity Dependence: The company relies heavily on its diversified securities portfolio (utility stocks) to offset operating expenses and fund growth. A significant decline in this portfolio could impact liquidity.
• Regulatory: Operations are subject to FDA and New York State Department of Health regulations.

Investor Verification Checklist

• Revenue Sustainability: Verify the durability of the 54% increase in operating revenues and the conversion rate of the 12 Q1 2000 instrument orders into recurring reagent sales.
• Investment Portfolio Volatility: Assess the risk exposure of the $34.9 million securities portfolio, which constitutes the majority of assets and funds operations.
• Cash Flow from Operations: Note that despite a reduced net loss, net cash provided by operating activities was negative ($471,201), indicating continued reliance on investment sales or financing for cash needs.
• Debt Covenants: Review terms of the $2.44 million in short-term debt, which is secured by the marketable securities portfolio.
• Clinical Validation: Monitor the publication of the septic shock study results, which management cites as a critical driver for future demand.